Range Financial Group LLC Purchases 11,167 Shares of Johnson & Johnson (NYSE:JNJ)

Range Financial Group LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 509.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,357 shares of the company’s stock after acquiring an additional 11,167 shares during the period. Range Financial Group LLC’s holdings in Johnson & Johnson were worth $1,932,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Canandaigua National Trust Co of Florida lifted its position in Johnson & Johnson by 13.2% during the fourth quarter. Canandaigua National Trust Co of Florida now owns 2,250 shares of the company’s stock valued at $325,000 after purchasing an additional 263 shares in the last quarter. Capital Market Strategies LLC lifted its position in Johnson & Johnson by 5.8% during the fourth quarter. Capital Market Strategies LLC now owns 7,723 shares of the company’s stock valued at $1,117,000 after purchasing an additional 425 shares in the last quarter. Pensionfund Sabic lifted its position in Johnson & Johnson by 49.2% during the fourth quarter. Pensionfund Sabic now owns 27,300 shares of the company’s stock valued at $3,948,000 after purchasing an additional 9,000 shares in the last quarter. Nordea Investment Management AB lifted its position in Johnson & Johnson by 13.7% during the fourth quarter. Nordea Investment Management AB now owns 6,424,675 shares of the company’s stock valued at $926,438,000 after purchasing an additional 775,490 shares in the last quarter. Finally, Versant Capital Management Inc lifted its position in Johnson & Johnson by 27.8% during the fourth quarter. Versant Capital Management Inc now owns 4,678 shares of the company’s stock valued at $677,000 after purchasing an additional 1,019 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on JNJ shares. Morgan Stanley lifted their target price on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Guggenheim boosted their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Finally, Royal Bank of Canada boosted their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $174.71.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded up $2.53 during mid-day trading on Tuesday, reaching $146.19. The stock had a trading volume of 8,408,107 shares, compared to its average volume of 7,061,887. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The company has a market cap of $351.97 billion, a P/E ratio of 21.16, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51. Johnson & Johnson has a 1 year low of $142.75 and a 1 year high of $168.85. The business’s 50 day moving average price is $151.03 and its 200 day moving average price is $156.25.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. During the same period in the previous year, the firm posted $2.66 earnings per share. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. Research analysts expect that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.39%. Johnson & Johnson’s dividend payout ratio is 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.